Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study - Wikidata - awgldk - TriplyDB

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

http://www.wikidata.org/entity/Q24658546

about

Treatment of diabetic retinopathy: Recent advances and unresolved challenges Relation between macular morphology and treatment frequency during twelve months with ranibizumab for diabetic macular edema A Review of Ranibizumab for the Treatment of Diabetic Retinopathy.Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases Clinical practice pattern in management of diabetic macular edema in Japan: survey results of Japanese retinal specialists.Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature.Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom.Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges.Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol.Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials.Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema.Management of diabetic macular edema in Japan: a review and expert opinion.Real world evidence of use of anti-VEGF therapy in Denmark.Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting.

P2860

Q28067491-1CF0EA0D-2CF3-444E-A20C-C9468129AF55 Q33563100-1C3CD6F6-AF2D-4AE2-91E1-8950874EAB23 Q33740152-1EE76E99-348F-4E3C-96A6-EF7094782320 Q33840787-E0DDCEA9-C2E9-48EB-92DB-062B62A22620 Q36159029-1FBDC821-8174-4714-850B-E155F31999AA Q38845769-6DCB02A1-7891-4E92-BCA3-84EAF4604875 Q39010176-7A37B6DC-D780-4CD3-98BE-63205DBF13C2 Q39292954-30DC6783-4405-4FF9-BAF2-4A3FE7867AE6 Q42150402-69E5420E-6108-4379-80B6-E63281A5FB97 Q42602540-26CF8CC6-6B13-4CDD-86E2-79F4E910F836 Q47310979-0B0B802F-23CE-4F9A-9817-3B2FCE44AE22 Q48316496-309080A3-3002-4FCF-AB08-C1D6790BB094 Q48579709-783C1EF8-3F33-4927-85C9-46CD59E9EAFB Q50571685-3DA06E1F-A452-4DA1-9861-76B836ADEDC7 Q55162753-3551C402-1195-451A-BFCB-1DD6B2AF24CC

P2860

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

http://www.wikidata.org/entity/Q24658546

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

name

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

@ast

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

@en

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

@nl

type

label

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

@ast

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

@en

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

@nl

prefLabel

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

@ast

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

@en

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

@nl

P1433

Q24658546-0C7E569F-7269-47BE-836B-86DE23DC8A95

P1476

Q24658546-064BBF21-F3B8-484D-8D0A-27E9F237677C

P2093

Q24658546-068C79F2-7518-44AD-ADCC-3E49C86865B7

Q24658546-1920ED5A-FE6C-474F-A377-D2B0F142D4A5

Q24658546-2F491C69-375D-4695-B06C-4ED41449D623

Q24658546-352A93A5-D7F8-4ACA-8F64-6C891A00028F

Q24658546-4CB0EF75-B098-4818-B588-A24349C3A48B

Q24658546-761565B4-976D-4FA9-A246-44589BCEE9A9

Q24658546-80EBE84F-654A-4021-9D63-9212AA13231A

Q24658546-A3C79A49-F947-4A11-B7FB-EC1F96CB3B8F

Q24658546-CE5DFB6D-743C-4118-BAED-287FB396C5CA

Q24658546-DDD89BAA-437C-4871-A96C-05B1C73F8B6F

P2860

Q24658546-10C3C586-FD4C-475F-A0AA-025330A37908

Q24658546-1EBCD609-CAA3-41FB-B788-85CF7F585DEF

Q24658546-26B1A102-523B-4676-BA1E-5EAB429228C7

Q24658546-36C05F10-F542-4444-9693-5F6B6C39FE8C

Q24658546-41626270-5722-4188-A358-1132962FCF06

Q24658546-459630F0-621A-4587-8938-5550397078B2

Q24658546-6BDF920D-2239-48D6-AD35-B0989FD54C6C

Q24658546-7CF4DE96-CC2B-49C6-9FD9-1333329799E2

Q24658546-7E769A7B-C7F4-4556-A7C6-44B3E4C050B5

Q24658546-8ADC3EE7-02B9-4983-B099-6849591DB623

P304

Q24658546-CDA58C37-0ADA-4F2F-B488-8211E3AF61B3

P31

Q24658546-4E06C382-2A70-414E-A26B-909608C42D42

P3181

Q24658546-DE6BBC60-6BCA-4436-AA51-35986AAA6E51

P356

Q24658546-C4280285-8230-4D70-9379-47B75C1C31FF

P407

Q24658546-460E3748-1AF1-4380-9245-1FD891161EF8

P433

Q24658546-D10D3372-CB19-4CDA-9A34-F0A3BC690DC8

P478

Q24658546-5A01F2D0-A114-44FA-AC40-AD0B5B3A027F

P50

Q24658546-98D8D1F4-EDDB-4D1E-9E40-E658D90CCF63

P577

Q24658546-5669628C-7E01-474B-8934-E005D189A82F

P698

Q24658546-8DF007F2-5CA8-443C-8CF2-A1248C5647CE

P932

Q24658546-F36FFDB5-9BD1-4F1C-A0AF-767B17153693

P3181

P356

BJOPHTHALMOL-2015-307249

P1433

British Journal of Ophthalmology

P1476

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

@en

P2093

Andreas Wenzel

http://www.w3.org/2001/XMLSchema#string

Christian Prünte

http://www.w3.org/2001/XMLSchema#string

Federico Ricci

http://www.w3.org/2001/XMLSchema#string

Franck Fajnkuchen

http://www.w3.org/2001/XMLSchema#string

João Figueira

http://www.w3.org/2001/XMLSchema#string

Katja Hatz

http://www.w3.org/2001/XMLSchema#string

RETAIN Study Group

http://www.w3.org/2001/XMLSchema#string

Sajjad Mahmood

http://www.w3.org/2001/XMLSchema#string

Soumil Parikh

http://www.w3.org/2001/XMLSchema#string

Vladimir Bezlyak

http://www.w3.org/2001/XMLSchema#string

P2860

Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.

Diabetic macular edema: pathogenesis and treatment.

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study.

Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results

Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.

Burden of illness of diabetic macular edema: literature review.

Diabetes mellitus and the heart.

Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment.

P304

787-795

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

798037

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/BJOPHTHALMOL-2015-307249

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26453639

http://www.w3.org/2001/XMLSchema#string

P932

4893084

http://www.w3.org/2001/XMLSchema#string